leisure time -WSS

leisure time

author：comprehensive 2025-09-27 23:54:00 - browse：86

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Abbott's new heart device gets FDA advisory panel nod

WSS

Juul documents reveal insider tactics on political lobbying

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Making the case for fair compensation in clinical trials

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Fentanyl is making it harder to start addiction treatment

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

entertainment

Supreme Court strikes down use of affirmative action

UnitedHealth argues against case alleging wrongful AI care denials

After affirmative action ruling, medical educators look to 'holistic review'

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Bright Health sells Medicare Advantage business to Molina

As a primary care physician, here's how I hope to partner with AI

Medical leaders decry Supreme Court decision on affirmative action

Reports of telehealth's death have been greatly exaggerated

Hollywood unions extend contract negotiations for actors

Fentanyl is making it harder to start addiction treatment

explore

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Ebola vaccine can save some who are already sick, per new study

Latigo launches with $135 million for Vertex

Why Eli Lilly’s earnings didn’t quite live up to the hype

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

focus

Wikipedia

leisure time

hotspot